Market research
2KZ.F Kezar Life Sciences, Inc
F EUR Healthcare
Latest close
As of 26 Jan 2025
Test a moving-average rule with historical data.
Market facts
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- 14.75
- Dividend yield
- Not available
- Beta
- 0.21
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- 14.75
- Dividend yield
- Not available
- Beta
- 0.21
About
About Kezar Life Sciences, Inc
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Research context
Kezar Life Sciences, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 2KZ.F discussion.
5 years, 6 months ago
Kezar Life Sciences, Inc is currently in a long term downtrend where the price is trading 0.9% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Kezar Life Sciences, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 14.2% to $-11M since the same quarter in the previous year.
Finally, its free cash flow fell by 29.9% to $-9M since the same quarter in the previous year.
Based on the above factors, Kezar Life Sciences, Inc gets an overall score of 1/5.